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Background: Rate of lung function decline (RLFD) (as FEV1 percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a
study endpoint, in part due to uncertainty of sample size requirements.
Methods: Sample size requirements for 1:1 randomizations to detect RLFD treatment effects from 20% to 80% were assessed in Epidemiologic
Study of CF (ESCF) patients. Effects of measuring FEV1 1–4 times per year in studies of 1- to 4-year durations were assessed in 399 patients age
≥6 years with FEV1 ≥70%. Impacts of inclusion/exclusion based on risk factors in 2369 ESCF patients were assessed over 1.5 years using semi-
annual FEV1 measures.
Results: Increasing study duration and exclusion of lower risk patients (e.g., no P. aeruginosa infection) both substantially reduced requirements.
Conclusions: CF RLFD studies of 1.5 years in duration appear feasible provided that investigators account for the beneficial effects of subject
inclusion/exclusion based on risk factors in power estimates.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Study design; Rate of decline; Sample size1. Introduction
Cystic fibrosis (CF) is a life-shortening genetic disease in
which 80% of deaths directly or indirectly result from loss of
pulmonary function [1]. Previous CF studies have suggested
that: patients who die at an earlier age experience, on average, a
more rapid rate of decline of forced expiratory volume in 1
second (FEV1) over their lifetimes [2]; a patient's rate of FEV1
decline can be used to estimate their age of death [3]; the
presence or absence of certain risk factors can help predict
future rate of decline [4]; and, chronic therapeutic interventions
can slow FEV1 decline [5–7]. For these reasons, demonstration
of a reduction in the mean rate of FEV1 decline compared with⁎ Corresponding author. 12520 33rd St Ct E, Edgewood, WA 98372, USA.
Tel.: +1 253 370 5859; fax: +1 253 661 9508.
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doi:10.1016/j.jcf.2010.05.004placebo has been proposed as a basis by which a CF respiratory
therapy can be determined to be disease modifying [8].
Chronic respiratory therapies have become an increasingly
prominent component of CF patient management today,
although the most commonly used therapies have not been
shown to reduce rate of FEV1 decline, but rather to produce a
sustained improvement in FEV1 compared with placebo-treated
controls [9]. Use of rate of FEV1 decline as a prospective
clinical trial endpoint remains a desirable but elusive goal for
CF drug development in part because of individual variability in
FEV1 over time [8]. The effect of this variability is mitigated as
study duration increases, which may partially explain why the
only prospective controlled clinical trial in CF to demonstrate a
significant reduction in the rate of FEV1 decline to date has been
a 4-year study of high-dose ibuprofen [5]. A 2-year study of
ibuprofen demonstrated an effect on rate of forced vital capacity
(FVC) decline, but did not reach significance for FEV1 declined by Elsevier B.V. All rights reserved.
Table 1
Demographics of study population.
Variable Development Stratification




Range 34.9 (6.0–40.9) 52.0 (6.0–58.0)
Baseline FEV1, % predicted
Mean±SD 89.8±14.0 91.2±14.5
Median 88.0 90.1
Range 62.7 (70.0–132.7) 72.3 (70.0–142.3)
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week study of inhaled hypertonic saline failed to reach primary
FEV1 rate of decline endpoints [11,12] Although challenging, it
has been possible to establish a CF therapy's impact on rate of
FEV1 decline using patient registries. The efficacy of high-dose
ibuprofen has been recently confirmed using the Cystic Fibrosis
Foundation (CFF) Patient Registry [6] and an effect of inhaled
corticosteroids on rate of FEV1 decline has been demonstrated
using the Epidemiologic Study of Cystic Fibrosis (ESCF) [7].
These results suggest that retrospective analyses of CF
patient registries might help better define design parameters for
prospective randomized controlled studies that employ rate of
FEV1 decline as an efficacy endpoint. We have used data from
the ESCF [13] to assess the impact of study duration, sampling
frequency, inclusion/exclusion criteria, and magnitude of
proposed treatment effects on study power and sample size
requirements using rate of FEV1 decline as an efficacy
endpoint.
2. Methods
Data were obtained from ESCF, a prospective, encounter-
based, multicenter, observational study designed to evaluate the
natural history of CF patients in North America from 1994 to
2005 [12]. Informed consent was obtained according to local
human subjects review boards. Pulmonary function test (PFT)
results were reported as measured values and converted to
percent predicted using reference equations from Wang et al.
[14] for females through age 15 and males through age 17, and
Hankinson et al. [15] at older ages.
Analyses were performed in two parts using SAS version 9.1
(SAS Institute, Inc., Cary, NC). First, the effects on sample size
requirements of frequency of FEV1 measurement and the
duration of time over which measures are collected were
assessed in a development population set. Next the effects of
various risk factors for lung function decline [4] were assessed
in a separate stratification population set using a single
frequency and duration of measure selected from the develop-
ment set analysis. For the development set, patients from ESCF
were selected who had a clinic visit during which they were
clinically stable ≥1 year after ESCF enrollment and within ±1
calendar year of their 1998 birthday, were ≥6 years of age and
had an FEV1 ≥70% predicted at that visit, and had at least
quarterly PFT results available over the subsequent 4-year time
period. Only one PFT measure closest to each quarterly interval
was used for analyses, with additional measures discarded.
Rates of FEV1 decline (as percent predicted/yr) and associated
SD were calculated for the development set as functions of
sampling frequency (ranging from quarterly to annual FEV1
measures) and duration of measure (ranging from 1 to 4 years).
Sample sizes required to retain 80% power to detect significant
(p=0.05) relative differences in rate of FEV1 decline ranging
from 20 to 80% in 1:1 randomized studies were estimated for
each frequency/duration combination. This analysis was then
used to choose a single frequency of FEV1 measure and
duration of study for subsequent stratification set analyses. The
single frequency and duration of measure chosen for subsequentanalyses was infrequent and short (respectively) in order to
increase the number of available ESCF patients, while at the
same time retaining sample sizes comparable to previous
studies conducted in CF patients.
Relaxed inclusion criteria identified by development group
analyses were then used to identify a group of ESCF patients
large enough that sample size calculations could be conducted
on subgroups stratified by risk factors for rate of FEV1 decline
(the stratification group). The stratification dataset was
composed of patients from ESCF that met all of the
development set inclusion criteria except that they only needed
FEV1 measures available at the selected single sampling
frequency and duration of measure chosen based on the results
of the development set analyses. In order to assess the impact of
risk factors [4] on sample size requirements, these stratification
group patients were divided by age group (6–12, 13–17, 18–24,
≥25 years of age), FEV1 (70 to b85, 85 to b100, ≥100%
predicted), weight-for-age percentile (b25th,≥25th percentile),
prior year history of P. aeruginosa culture results (all negative,
any positive), and prior year history of exacerbations treated
with intravenous (IV) antibiotics (IV exacerbations; 0, 1, 2,
≥3). Rates of FEV1 change (as percent predicted/yr) and
sample sizes required for 1:1 randomized studies to retain 80%
power (α=0.05) to detect effects on rate of FEV1 decline
ranging from 20 to 80% were calculated for stratification set
subgroups.
3. Results
A total of 399 of 32,585 ESCF patients met the inclusion
criteria for the development set, with a mean age of 12.5±5.7
(SD) years and mean FEV1 of 89.8±14.0% predicted (Table 1).
Estimated mean rates of FEV1 decline and associated SD
decreased incrementally as the duration of measure increased
from 1 year to 4 years and as frequency of measure increased
from annual to quarterly (Fig. 1A and B). Sample sizes required
to detect various treatment effects with 80% power and α=0.05
assuming a 1:1 randomization were plotted for different
frequencies of measure and durations of study (Fig. 2;
Table 2). Changing the frequency of FEV1 measurement had
only a modest effect on sample sizes required to detect a given
treatment effect, with quarterly measures requiring slightly
higher sample sizes than other frequencies. For example,
detection of a 50% treatment effect in a 4-year study using
Fig. 1. Effect of frequency and duration of measure on estimated means and
standard deviations of rate of FEV1 change. Panel A, estimated mean rates of
FEV1 change as a function of duration of measure beginning at the index visit.
Bars represent standard errors (SE) around each mean. Panel B, observed
standard deviations for estimated rates of FEV1 change in Panel A. Estimates are
derived using annual (black circles), semiannual (gray circles), and quarterly
(white circles) FEV1 measures.
Fig. 2. Samples sizes required to detect treatment effects as functions of
frequency of measure and study duration. The number of subjects required per
arm in a 1:1 randomized study (80% power, α=0.05) to detect a given treatment
effect on rate of FEV1 change are plotted. Horizontal dotted line highlights a
50% treatment effect. Panel A, effect of collecting FEV1 measures quarterly
(light gray line), semiannually (dark gray line), and annually (black line) for a
duration of 4 years. Panel B, effect of study durations of 1 year (gray dashed
line), 1.5 years (black dashed line), 2 years (light gray line), 3 years (black line),
and 4 years (dark gray line) using semiannual measures. Note that dark gray
lines (semiannual FEV1 measures for 4 years duration) are the same in each
panel.
Table 2
Sample sizes required to detect a 50% reduction in rate of decline as a function
of study duration and measurement frequency.
Subjects required per arm a






1.00 374 315 320
1.25 321 – –
1.50 274 223 –
1.75 301 – –
2.00 268 190 200
2.25 239 – –
2.50 223 171 –
2.75 221 – –
3.00 211 162 164
3.25 193 – –
3.50 182 148 –
3.75 180 – –
4.00 175 143 138
a 1:1 randomization, 80% power, α=0.05.
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and 175 subjects per arm, respectively (Fig. 2A). Increasing
study duration had a more dramatic effect on required sample
sizes, with each increase in study duration leading to a further
decrease in required sample sizes (Fig. 2B). Detection of a 50%
reduction in rate of FEV1 change using semiannual FEV1
measures for 1 year required 315 subjects per arm, whereas
increasing study duration by an additional 6 months reduced the
required sample size by more than a quarter to 223 subjects per
arm. Increasing study duration an additional 6 months (to
2 years) only decreased the required sample size an additional
14.8% to 190 subjects per arm (Fig. 2B). Based on these results,
we selected a semiannual sampling frequency and 1.5-year
study duration for subsequent analyses with the expectation that
more ESCF patients would be available for analyses with these
less stringent inclusion criteria.When inclusion criteria for the stratification set were relaxed
to include patients having at least semiannual FEV1 measures
for 1.5 consecutive years after the index visit, a total of 2369
Table 4
Distribution of risk factors for decline in the stratification set.
Age range, yrs
6–12 13–17 18–24 ≥25
Sample size, n 1,441 616 206 106
FEV1 % predicted, n (%)
70 to b85 439 (30.5%) 288 (46.8%) 133 (64.6%) 74 (69.8%)
85 to b100 520 (36.1%) 210 (34.1%) 52 (25.2%) 29 (27.4%)
≥100 482 (33.4%) 118 (19.2%) 21 (10.2%) 3 (2.8%)
Weight-for-age percentile, n (%)
≥25th 803 (55.7%) 369 (59.9%) 120 (58.3%) 76 (71.7%)
b25th 637 (44.2%) 246 (39.9%) 85 (41.3%) 30 (28.3%)
P. aeruginosa culture history in the past year, n (%)
All negative 658 (45.7%) 179 (29.1%) 32 (15.5%) 13 (12.3%)
Any positive 685 (47.5%) 394 (64%) 157 (76.2%) 81 (76.4%)
IV exacerbations in the past year, n (%)
0 1001 (69.5%) 385 (62.5%) 93 (45.1%) 50 (47.2%)
1 274 (19%) 125 (20.3%) 53 (25.7%) 30 (28.3%)
2 95 (6.6%) 51 (8.3%) 33 (16%) 17 (16%)
≥3 71 (4.9%) 55 (8.9%) 27 (13.1%) 9 (8.5%)
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was 12.8 ± 5.9 years and mean FEV1 was 91.2 ±14.5%
predicted (Table 1). The mean rate of FEV1 change in the
stratification set over the 1.5 years from their index visit was
−4.1% predicted/yr (SD, 9.3), a smaller rate of FEV1 change
than observed under the same conditions for the development
set (−5.1±9.7% predicted/yr; Table 3). The stratification set
was composed of substantially more patients b18 years (2057)
than ≥18 years of age (312) (Table 4). The status of specific
baseline risk factors previously shown to affect rate of FEV1
decline in CF children and adolescents [4] was not available for
all patients in the stratification group, but distributions of
presence or absence of risk factors among those with available
data appeared to reflect demographics of the general CF
population. For example, older age groups had proportionally
fewer patients with FEV1 ≥100% predicted when compared
with younger groups. There was evidence of a survivor effect
among the 106 patients ≥25 years of age, in that the proportion
with weight-for-age ≥25th percentile was higher than that of
the 18- to 24-year-old group (71.7% versus 58.3%, respective-
ly), whereas the proportion having ≥2 IV exacerbations in the
previous year was lower (24.5% versus 29.1%, respectively)
(Table 4).
Stratification by baseline FEV1 and subject age dramatically
affected estimated mean rates of FEV1 change and
corresponding sample size estimates (Fig. 3). In general,
estimated sample sizes decreased as patients with higher
baseline lung function were included, in all age groups studied
(Fig. 3B). Inclusion of children between 6 and 12 years of age
substantially increased sample sizes required to detect a 50%
treatment effect when compared with sizes required for other
age groups, particularly when baseline FEV1 was b100%
predicted. For example, studies of 6- to 12-year-olds with
baseline FEV1 between 85 to b100% and 70 to b85% predicted
were estimated to require 1078 and 1378 subjects per arm,
respectively (Fig. 3B). By comparison, studies conducted in 13-
to 17-year-olds within the same pulmonary function categories
were estimated to require only 170 and 127 subjects per arm,
respectively.
Stratification of patients by weight-for-age percentile at their
index visit and by prior year history of P. aeruginosa culture
positivity or IV exacerbation also affected required sample sizes
(Fig. 4, Table 5). The sample size required to detect a 50%
treatment effect for subjects with an index weight-for-age below
the 25th percentile was 35.6% lower than for subjects with
higher weight-for-age percentiles (255 versus 396 subjects perTable 3










arm to detect a
50% effecta,b
Development 399 −5.1 9.7 223
Stratification 2369 −4.1 9.3 323
a Semiannual FEV1 measures for 1.5 yrs.
b 1:1 randomization, 80% power, α=0.05.arm). More dramatically, 68.9% fewer subjects with a history of
at least 1 respiratory culture positive for P. aeruginosa in the
prior year were required to detect a 50% treatment effect when
compared with subjects with no positive cultures in the prior
year (215 versus 691 subjects per arm). History of IV
exacerbation in the prior year also affected sample sizes; a
study in subjects with 1 prior IV exacerbation required 50.8%
fewer subjects to detect a 50% treatment effect than a study in
subjects with no exacerbations in the prior year (242 versus 492
per arm). As the number of IV exacerbations in the prior year
increased, sample sizes required to detect a 50% treatment effect
decreased correspondingly (Fig. 4, Table 5). Further stratifica-
tion of risk factors by subject age provided even greater
decreases in sample size estimates. For example, exclusion of 6-
to 12-year-olds from analyses uniformly reduced sample size
estimates, including a 57.1% reduction in the estimate for
subjects with no history of IV exacerbations in the prior year
and a 60.0% reduction for subjects with weight-for-age b25th
percentile (Table 5).
4. Discussion
Demonstration of a reduction in the mean rate of FEV1
decline compared with placebo has been proposed as a basis by
which a CF respiratory therapy can be determined to be disease
modifying [8]. This standard has been met in a prospective
clinical trial by only 1 chronic CF therapy [5,10]. For other
(more commonly used) CF respiratory therapies, claims of a
pulmonary function benefit have been based on sustained
improvement in FEV1 in treated subjects compared with
subjects receiving placebo, not rate of decline [16–18].
Although sustained FEV1 improvement is an endpoint that
can be reached in studies of shorter duration, sustained
improvement does not necessarily lead to a decreased rate of
FEV1 decline [8]. In addition, recent and ongoing shifts in the
demographics of the CF population have made it a more
challenging endpoint to execute than in the past [9].
Fig. 3. Effect of stratification by age and pulmonary function on rate of decline
and sample size requirements. Panel A, mean rates of FEV1 change when
measured semiannually over 1.5 years for 2369 subjects stratified by age and
pulmonary function. Bars represent standard errors. Panel B, number of subjects
required per arm to detect a 50% treatment effect in a 1:1 study with 80% power
(α=0.05) in the same population.
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design and powering of CF studies that use rate of FEV1 decline
as an efficacy endpoint. Our analysis complements a previous
regression analysis estimating future rate of FEV1 decline in
children and adolescents with CF as a function of the presence
or absence of specific risk factors [4]. We have focused on CF
patients with a baseline FEV1 ≥70% predicted because these
patients have been shown to be at the greatest risk for FEV1
decline in the near future [4].
For simplicity, we chose to examine the effects of risk factors
for lung function decline on sample size requirements using a
single study duration (1.5 years) and frequency of FEV1
measure (semi-annual). Although best-suited for our retrospec-
tive analysis, these choices will not necessarily be ideal for
future studies. For instance, although the choice of semi-annual
sampling allowed us to increase the number of available ESCF
patients, quarterly assessments are likely to be necessary infuture controlled clinical trials to ensure collection of additional
efficacy and safety data. For this reason, the specific sample
sizes arising from our analyses are perhaps less important than
suggestions of how study designs and population selection can
increase the power of studies using rate of FEV1 decline as an
endpoint. Increasing the duration (and to a lesser extent, the
frequency) of measure reduces both the observed rate of decline
(Fig. 1A) and its associated variance (Fig. 1B), probably by
regression to the mean. This produces opposing effects on
sample size requirements, with decreasing rates of FEV1 change
requiring relatively more subjects to detect a given treatment
effect and lowering variance having the opposite effect. Our
results suggest that the benefit of reduced variance eclipses the
disadvantage of a lower rate estimates as study duration
increases, with studies of 1.5 years of sufficient duration to
reduce variance to levels where reasonable sample sizes can be
chosen while retaining 80% power to detect a treatment
difference.
Stratification of study populations by exclusion of subjects at
lower risk of immediate FEV1 decline (e.g., subjects 6–12 years
old or without specific risk factors) further reduces sample size
requirements by both increasing the expected mean rate of
FEV1 decline and decreasing the variance associated with these
rates. It is important to note that conclusions drawn for certain
subpopulations have been made with relatively small numbers
of patients. For example, few patients that were ≥18 years of
age with FEV1 ≥100% predicted were available for this
analysis (Table 1).
Our results suggest that two previous randomized controlled
1-year-long studies of CF respiratory therapies appear to have
been substantially underpowered to reach their primary FEV1
rate of decline endpoints, primarily due to short trial durations.
The open-label study of tobramycin inhalation solution in CF
children with early stage lung disease [11], in which 63% of
subjects were between 6 and 10 years of age, likely would have
required nearly a thousand subjects (as opposed to the 181
enrolled when the study was halted) to retain adequate power to
detect a difference in rate of FEV1 decline over the study period.
Similarly, the placebo-controlled study of hypertonic saline
[12], which included a substantial number of subjects with
FEV1 below 70% predicted (mean, 74% predicted; SD, 21%
predicted; range 40–132% predicted) was also underpowered
with only 164 enrolled subjects. However, retrospective
analyses of the powering of previous CF studies using rate of
lung function decline should be considered in the context of
how changes in management and demographics may have
altered rates of FEV1 decline in the population. For instance, the
placebo rate of decline in the high-dose ibuprofen study over
4 years was −3.60% predicted/yr [5], while the corresponding
rate from our ESCF development set was predicted to be
−2.42% predicted/yr. This one-third reduction in decline rate
has a dramatic impact on sample size estimates: our analyses
suggest that over 270 subjects per arm (Fig. 2B) would be
required from our development set to detect the 40% reduction
in rate of decline observed in the ibuprofen trial, while a little
over 40 subjects per arm successfully demonstrated the effect in
the actual study. Interestingly, investigators designing a 2-year
Fig. 4. Effects of inclusion or exclusion of other risk factors for FEV1 decline on sample size estimates. Sample sizes required per study arm to retain 80% power
(α=0.05) to detect a 50% change in rate of FEV1 decline over 1.5 years using semiannual measures as a function of risk factor status. Risk factors are shown at the top
separated by dashed lines. Status for each risk factor is shown at the bottom. Estimated sample sizes required per arm are shown above the bars.
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observed placebo rate of decline (−2.7% predicted/yr) [10]. The
feasibility of increasing power in a study using rate of FEV1
decline as an endpoint by including subjects at higher risk for
decline should be considered in the context of the overallTable 5
Estimated RLFDa and samples size requirements b by age and risk factors.
Age range, yrs




−3.5 −5.0 −4.7 −3.7 −2.5 −5.2 −5.4
Sample size 396 192 170 182 787 201 158
b25th FEV1 change
(% pred/yr)
−4.9 −6.9 −7.0 −10.7 −3.8 −6.8 −5.7
Sample size 255 102 93 58 464 106 109





−2.7 −4.8 −4.4 −2.5 −2.0 −4.9 −5.1





−5.2 −6.2 −5.8 −6.2 −4.3 −6.4 −5.6
Sample size 215 124 127 110 364 122 137
IV exacerbations in the past year
0 FEV1 change
(% pred/yr)
−3.1 −4.5 −3.7 −3.8 −2.4 −4.7 −3.7
Sample size 492 211 205 228 852 210 194
1 FEV1 change
(% pred/yr)
−4.9 −5.9 −5.8 −6.6 −4.1 −6.1 −5.3
Sample size 242 134 103 106 386 153 100
2 FEV1 change
(% pred/yr)
−5.8 −7.9 −7.7 −8.7 −3.6 −8.1 −7.3
Sample size 172 73 85 60 519 78 101
≥3 FEV1 change
(% pred/yr)
−9.0 −10.3 −9.0 −7.5 −7.4 −11.1 −9.6
Sample size 98 68 94 108 162 56 92
a Derived from 1.5 years of semiannual measures.
b 80% power to detect a 50% change in rate of FEV1 change over 1.5 years
with semiannual FEV1 measure, α=0.05, in CF subjects with FEV1≥70%
predicted.distribution of CF patients in the population (Table 6). For
example, we report in our analysis that only 56 subjects per arm
ages 13 to 17 years old, with FEV1≥70% predicted and ≥3 IV
exacerbations in the previous year, would have been required to
retain 80% power to detect a 50% reduction in rate of FEV1
decline over 1.5 years (Table 5). However, only 224 of the
patients reported in the CFF Patient Registry in 2008 [1] had
these characteristics (Table 6). Thus, a study limited to this
population would require enrollment of over half of all eligible
patients in the US, with allowances for anticipated dropouts
further increasing requirements. The challenge going forward
will be to account for the prevalence of the most potentially
useful CF subpopulations when designing FEV1 rate of decline
studies intended to have increased power.Table 6
Distribution of CF patients with FEV1≥70% predicted followed in the 2008
Cystic Fibrosis Foundation Patient Registry [1].
Age range a, yrs
≥6 6–12 13–17 18–24 ≥25
Patients, n 12,972 4992 3300 2427 2253
FEV1 % predicted
b, n
70 to b85 5108 1267 1266 1288 1287
85 to b100 4281 1681 1129 786 685
≥100 3583 2044 905 353 281
Weight-for-age percentile c, n
≥25th 8910 3234 2232 1633 1811
b25th 4060 1758 1068 794 440
P. aeruginosa culture history in 2007, n
All negative 3143 476 802 962 903
Any positive 8478 4263 2284 1151 780
IV exacerbations in 2007, n
0 9010 3657 2097 1575 1681
1 2527 956 714 502 355
2 851 261 265 194 131
≥3 584 118 224 156 86
a Age as of Jan 1, 2008.
b First available FEV1 measure in 2008.
c First available weight-for-age percentile measure in 2008.
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